{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:27:17Z","timestamp":1791822437333,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2016.02.027","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T18:19:17Z","timestamp":1455733157000},"page":"1832-1838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States"],"prefix":"10.1016","volume":"34","author":[{"given":"Hajime","family":"Kamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Messonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"RR-7","key":"10.1016\/j.vaccine.2016.02.027_bib0140","first-page":"1","article-title":"Pertussis vaccination: use of acellular pertussis vaccines among infants and young children","volume":"46","author":"CDC","year":"1997","journal-title":"MMWR"},{"issue":"RR-17","key":"10.1016\/j.vaccine.2016.02.027_bib0145","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR"},{"issue":"RR-3","key":"10.1016\/j.vaccine.2016.02.027_bib0150","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0155","first-page":"131","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women \u2013 Advisory Committee on Immunization Practices (ACIP), 2012","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR"},{"issue":"53","key":"10.1016\/j.vaccine.2016.02.027_bib0160","first-page":"1","article-title":"Summary of notifiable diseases \u2013 United States, 2012","volume":"61","author":"CDC","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0165","first-page":"625","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2013","volume":"63","author":"CDC","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0170","first-page":"95","article-title":"Noninfluenza vaccination coverage among adults \u2013 United States, 2012","volume":"63","author":"CDC","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0175","unstructured":"CDC. Advisory Committee on Immunization Practices (ACIP) Summary Report. February 20\u201321, 2013. Atlanta, GA."},{"issue":"June (6)","key":"10.1016\/j.vaccine.2016.02.027_bib0180","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1542\/peds.2014-3358","article-title":"Tdap vaccine effectiveness in adolescents during the 2012 Washington State Pertussis Epidemic","volume":"135","author":"Acosta","year":"2015","journal-title":"Pediatrics"},{"issue":"September (6)","key":"10.1016\/j.vaccine.2016.02.027_bib0185","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/infdis\/jiu322","article-title":"Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand","volume":"210","author":"Koepke","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.02.027_bib0190","first-page":"1","article-title":"United States Life Tables, 2008","volume":"61","author":"Arias","year":"2012","journal-title":"Natl Vital Stat Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2016.02.027_bib0195","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1086\/655825","article-title":"Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults","volume":"51","author":"Mertsola","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2016.02.027_bib0200","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.vaccine.2011.07.068","article-title":"Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4\u20135 years after a previous dose","volume":"29","author":"Halperin","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.02.027_bib0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4161\/hv.6.7.11760","article-title":"Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix\u2122 IPV)","volume":"6","author":"Knuf","year":"2010","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2016.02.027_bib0210","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.vaccine.2011.11.035","article-title":"Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.02.027_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.vaccine.2010.10.025","article-title":"A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix\u2122) is immunogenic and well tolerated in adults","volume":"29","author":"Booy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0270","unstructured":"Truven Health Analytics, Truven Health MarketScan\u00ae Research Databases, 2003\u20132010."},{"key":"10.1016\/j.vaccine.2016.02.027_bib0220","unstructured":"Bureau of Labor Statistics, Occupational Employment Statistics, May 2011, Department of Commerce, http:\/\/www.bls.gov\/oes\/2011\/may\/oes_nat.htm [accessed 17.10.14]."},{"issue":"August (36)","key":"10.1016\/j.vaccine.2016.02.027_bib0225","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1016\/j.vaccine.2009.06.038","article-title":"Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study","volume":"27","author":"Jackson","year":"2009","journal-title":"Vaccine"},{"issue":"February (10)","key":"10.1016\/j.vaccine.2016.02.027_bib0230","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.vaccine.2012.10.097","article-title":"U.S. postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005\u20132007","volume":"31","author":"Chang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.027_bib0235","unstructured":"CDC. CDC Vaccine Price list, http:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/2011\/2011-09-29.html [accessed 04.10.11]."},{"key":"10.1016\/j.vaccine.2016.02.027_bib0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7525-3-17","article-title":"Health-state valuations for pertussis: methods for valuing short-term health states","volume":"3","author":"Lee","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.vaccine.2016.02.027_bib0245","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/319853","article-title":"Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995\u20131996","volume":"183","author":"Strebel","year":"2001","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2016.02.027_bib0250","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa050824","article-title":"Efficacy of an acellular pertussis vaccine among adolescents and adults","volume":"353","author":"Ward","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2016.02.027_bib0255","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1996.03530450062034","article-title":"Prevalence and incidence of adult pertussis in an urban population","volume":"275","author":"Nennig","year":"1996","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2016.02.027_bib0260","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1542\/peds.2004-2509","article-title":"Pertussis in adolescents and adults: should we vaccinate?","volume":"115","author":"Lee","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2016.02.027_bib0265","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amepre.2006.10.016","article-title":"Cost effectiveness of pertussis vaccination in adults","volume":"32","author":"Lee","year":"2007","journal-title":"Am J Prevent Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:02:44Z","timestamp":1536969764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X16001699"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}